Studies were undertaken to determine the applicability and effectiveness of immunoadsorption chromatography on anti-low density lipoprotein (LDL) columns as a plasma-cholesterol-lowering procedure. Mass production and isolation of monospecific antibodies against swine LDL (p = 1.006-1.063 g/ml) was carried out by immunization of sheep with swine LDL and selective antibody adsorption from their antisera by chromatography on LDL-Sepharose. The isolated LDL antibodies were then covalently linked to Sepharose CL-4B. Pig plasma LDL was effectively removed in vitro by the anti-LDL-Sepharose beads. In vivo studies were performed in pigs with (i) a plasma-separator membrane permeable to solutes below M, 2,000,000 or (ii) a blood centrifuge interposed into an arteriovenous shunt to separate the corpuscular elements of blood from the plasma. In either case, the plasma was passed through the anti-LDL-Sepharose column and recirculated into the venous part of the shunt. Plasma cholesterol levels were reduced 70-80% by this procedure and rebounded 3-4 days after the extracorporeal immunoadsorption procedure. This continuous plasma separation-immunoadsorption procedure may have broad applicability for the elimination of any plasma component with antigenic properties.
Familial hypercholesterolemia (type II hyperbetalipoproteinemia) (1) is characterized by increased plasma cholesterol concentrations and increased plasma low density lipoprotein (LDL) levels. It has been established that this form of hypercholesterolemia is due to a reduced fractional catabolic rate and to a 2-to 3-fold overproduction of LDL (1) (2) (3) ; as a result, there is premature development of atherosclerosis.
Three independent studies have been reported (4-6) that were designed to reduce the plasma cholesterol concentrations in patients with familial hypercholesterolemia by nonsurgical methods: plasmapheresis techniques (4, 6) and extracorporeal removal of LDL by means of heparin-agarose beads in blood venous packs (5) . These approaches have produced transient reductions in plasma LDL levels.
We report a procedure that results in specific removal ofapolipoprotein B (apo B)-containing lipoproteins (VLDL and LDL) by immunoadsorption. This study was undertaken to evaluate (i) the extent to which plasma LDL can be removed in vitro by an anti-LDL-Sepharose immunoadsorbent and (ii) whether and to what extent LDL (and VLDL) can be removed by continuous extracorporeal immunoadsorption in swine. Monospecific LDL antibodies were prepared from the serum of sheep immunized against pig LDL and were covalently linked to Sepharose. When swine plasma was passed through a column of anti-LDLSepharose, LDL was absorbed from the plasma. In vivo studies in pigs were performed by shunting blood from the arterial branch between the common carotid artery and internal jugular vein, separating the blood into a cell concentrate and a plasma fraction by means of a selective plasma-separator membrane technique or a continuous-flow blood cell-separator centrifuge. The plasma fraction was passed over an anti-LDL-Sepharose column, and the LDL-depleted plasma was recycled into the cell concentrate and returned to the animal through the venous branch of the shunt. A comparison of continuous immunoadsorption and continuous heparin-Sepharose adsorption of LDL was also performed.
MATERIALS AND METHODS Animals. Swine from a local farm and Hanford minipigs (provided by Nattermann & Cie, Koln, Federal Republic of Germany) were used for in vivo studies. Pig blood was obtained from a local slaughterhouse.
Isolation of Low Density Lipoprotein. Plasma from heparinor EDTA-treated pig blood (1 mg/ml) was separated by centrifugation, and the LDL was isolated by ultracentrifugation in a 60 Ti rotor of a Beckman L5-65B centrifuge (7, 8) . For the first centrifugation, a density of 1.006 g/ml was achieved with KBr. The supernatant was removed, and the density of the infranatant was adjusted to 1.063 g/ml with KBr. After ultracentrifugation, the upernatant containing LDL with density 1.006-1.063 g/ ml was collected, sedimented at density 1 
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The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. of 1 week with 5 mg of LDL (1 mg of apo B) in 0.5 ml of phosphate-buffered saline suspended in 0.5 ml ofcomplete Freund's adjuvant. The increase in antibody concentration was followed by quantitative single radial immunodiffusion (9, 10) performed every other day. The maximum concentration (-25 mg of antibodies per ml of plasma) was reached after 4 wk. Pig LDL-antibody protein was isolated by recycling 50 ml of heparin-or EDTA-treated sheep plasma (1 mg/ml of blood) diluted with the same volume of saline over a LDL-Sepharose CL-4B column (bed volume, 250 ml) for 4-12 hr. Unbound proteins were eluted with saline (1200 ml), and adsorbed antibody protein was eluted as a single band with a 0.2 M glycine HCl buffer (pH 3. 0). Approximately 4 g ofsheep LDL-antibody protein was collected by repeating the immunoadsorption.
Preparation of Anti-LDL-Sepharose CL4B. Anti-pig LDL [390 mg in 100 ml of 0.2 M bicarbonate buffer (pH 9.3)] was added to 50 ml ofCNBr-activated Sepharose CL-4B and treated Thermostat as described above. As determined by Lowry protein measurements (11) of the supernatant, 350 mg (90%) of LDL-antibody protein was covalently linked.
Preparation of Heparin-Sepharose CL-4B. Heparin-Sepharose CL-4B was prepared as described (12) .
LDL Depletion ofPig Plasma by Immunadsorption in Vitro.
Heparin-treated pig plasma (100 ml) was passed through an anti-pig-LDL-Sepharose column (bed volume, 20 ml; flow rate, 3 ml/min). Plasma proteins were eluted with 150 ml of saline, and the bound LDL was desorbed with 250 ml of 0.2 M glycine'HCl buffer (pH 3.0).
LDL Adsorption from Pig Plasma in Vivo. An arteriovenous shunt was constructed between the common carotid artery and the internal jugular vein of pigs and was tunneled subcutaneously to the neck region. Surgical procedures and in vivo studies were performed in pigs under combined anesthesia [Stresnil (Azaperon) and Metomidat (Hypnodil), Janssen GmbH, (14) .
RESULTS
The aim of these studies was to determine the effectiveness of immunoadsorption for the specific removal of the apo B-containing plasma lipoproteins VLDL and LDL in vitro and in vivo.
In Vitro LDL Depletion of Swine Plasma. Anti-LDL Sepharose immunoadsorption. Increasing volumes of swine plasma (750, 1250, and 2950 ml) with LDL concentrations of 1.7 mg/ml of plasma were chromatographed over an anti-LDL-Sepharose column (350-ml bed volume, 6.5-cm inside diameter), and the effluent was analyzed for LDL by agarose electrophoresis of the concentrated eluate and for LDL cholesterol. The LDL concentration bound by immunoadsorption also was determined. Plasma proteins were eluted with saline, and LDL was desorbed with glycine HCl buffer (pH 3.0). For all three volumes tested, plasma cholesterol decreased from 112 to 40 mg/dl, and triglycerides decreased from 58 to 12 mg/dl; however, the total serum protein concentration remained unchanged. Total LDL bound equaled 117 ± 3 mg for each 100 ml of plasma passed through the anti-LDL-Sepharose column, representing a 64% reduction in LDL content.
Heparin-Sepharose CL-4B. The LDL-binding capacity of heparin-Sepharose was titrated as described above. A 450-ml heparin-Sepharose column was able to bind a maximum of 1550 mg of LDL (3.4 mg of LDL bound per ml ofcolumn volume), as compared to the binding of 3520 mg of LDL by the anti-LDLSepharose column (10.1 mg of LDL bound per ml of column volume). The total plasma protein concentration was diminished to about 70% by the heparin column.
In Vivo LDL Removal by Combined Plasma SeparationImmunoadsorption. The first masterflex pump transported arterial blood (50-120 ml/min) to the plasma-separator membrane which delivered about [25] [26] [27] [28] [29] [30] ml ofplasma per min to the anti-LDL-Sepharose column. The eluting plasma deprived of apo B-containing lipoproteins was returned to the concentrated blood by a second masterflex pump before entering the venous part of the shunt. This combined plasma-immunoadsorption procedure was performed over periods of [2] [3] [4] hr under light anesthesia. Aliquots of the arterial plasma before the plasma separator (Fig. 2, curve a) and of the plasma before (Fig. 2 , curve b) and after (Fig. 2, curve c ) the anti-LDL-Sepharose immunoadsorbent were taken for the determination of LDL cholesterol. Plasma LDL decreased by 50% within 20 min and reached 25% ofthe initial concentration during 2-3 hr of shunting (Fig. 2, curve a) . Extremely low LDL concentrations in the column effluent remained constant, demonstrating that the immunoadsorption of LDL did not exhaust the capacity ofthe bed volume of the immunoadsorbent during the duration of the experiment (Fig. 2, curve c) .
The anti-LDL-Sepharose column was regenerated by desorption of LDL with glycine buffer (pH 3.0) and immediate equilibration with phosphate-buffered saline. The anti-LDLSepharose column was stored at 40C under saline containing 0.01% NaN3. Prior to each experiment, the column was washed with sterile saline (= 10 liters). Under these conditions, no loss of LDL-binding capacity was observed over a period of 6 mo in more than 20 in vitro and in vivo experiments. Table 1 summarizes the results offour plasma separator-anti-LDL-Sepharose immunoadsorption experiments in pigs. With increasing volumes of blood passing through the shunt, there was a progressive decrease in the plasma LDL concentration. In experiment 4, the LDL concentration was decreased by 84%; the total plasma cholesterol was decreased from 115 to 35 mg/ dl, and triglycerides were decreased from 60 to 10 mg/dl. Electrolytes, total protein, glucose, uric acid, bilirubin, and serum enzyme concentrations (serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, y-glutamyl transpeptidase, alkaline phosphate) remained unaltered during these experiments. The heparin-Sepharose column also effectively removed LDL from the plasma, with a 72-79% reduction in LDL. Thus, the data indicate that the column performance in vivo was similar to that reported for in vitro studies and that a maximal binding capacity of 1600-1700 mg of LDL was observed.
Kinetics of the Blood LDL Replenishment. Blood LDL concentrations were measured daily because of the easy access to the shunt in the neck region of the experimental animal. Fig. 3 shows that the institution of the arteriovenous shunt caused an increase in LDL concentration from 1.0 to 1.8 mg/ml, and the plasma separation-immunoadsorption lowered LDL to 0.4 mg/ ml. The concentration of plasma HDL (1.6 mg/ml) remained constant during the immunoadsorption, and agarose electrophoresis of the lipoproteins desorbed from the column failed to reveal the presence of HDL. Three to 4 days later, the LDL concentration rebounded to 2.0 mg/ml (which exceeded the starting preoperative plasma LDL concentration by 50%), remained constant for 3-5 days, and then decreased to the initial LDL concentration of 1.0 mg/ml ofplasma.
LDL-Removal by Plasma Separation with Heparin-Sepharose. The kinetics of blood LDL replenishment following plasma separation by heparin-Sepharose chromatography is shown in Fig. 4 (26) ; lipoprotein lipase (27) ; and hepatic triglyceride lipase (28) ]. Ofpotentially greater importance is the observation that heparin columns also remove the HDL (29) that are considered to be protective against the development of arteriosclerosis (30) . The anti-LDL-Sepharose column appears to remove only apo B-containing lipoproteins, as judged by the fact that plasma HDL levels remain unchanged during immunoadsorption and that double immunodiffusion tests ofthe desorbed material from the column yield only one precipitin line with antipig plasma antibodies from rabbits.
In principle, this combination of plasma separation and immunoadsorption in an extracorporeal circulation should be applicable to the selective removal of any low molecular weight plasma component of endogenous or exogenous origin, provided that the component has antigenic properties.
The in vivo experiments were benefitted by the helpful collaboration with Prof. Sieberth, Medizinische Klinik der Universitat zu Koln. The Thyssen-Stiftung and the Deutsche Forschungsgemeinschaft supported these studies.
